DOCSLIB.ORG

Aldrich Raman Condensed Phase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Aldrich Raman Condensed Phase Aldrich Raman Condensed Phase Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo Scientific FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Condensed Phase Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'- 13183 (+)-B- BINAPHTHYL)PALLADIUM(II) CH METHOXYDIISOPINOCAMPHEYLB 10290 ((R)-(+)-3-HYDROXY-2- ORANE METHYLPROPYL)- 9005 (+)-BICUCULLINE, 98% TRIPHENYLPHOSPHONIUM 9410 (+)-BIOTIN 4-NITROPHENYL BROMIDE, 97% ESTER, 99% 10291 ((S)-(-)-3-HYDROXY-2- 4325 (+)-BIOTIN, 99% METHYLPROPYL)- 6982 (+)-BOLDINE HYDROCHLORIDE, TRIPHENYLPHOSPHONIUM 99% BROMIDE, 97% 236 (+)-CAMPHENE, TECH., 80% 6158 (+)-(4,6-O-BENZYLIDENE)METHYL- 8634 (+)-CARBOBENZYLOXY-D- ALPHA-D- GLUCOPYRANOSIDE, PROLINE, 98% 97% 6294 (+)-CATECHIN HYDRATE, 98% 13483 (+)-(S)-N,N-DIMETHYL-1-((R)-1',2- 11867 (+)-CINCHONINE, 85% BIS(DI- 753 (+)-CIS-P-MENTHANE-3,8-DIOL, PHENYLPHOSPHINO)FERROCENY 97% L)E 11734 (+)-CYTIDINE-5'- 1258 (+)-1,4-DIOXASPIRO(4.5)DECANE-2- MONOPHOSPHORIC ACID METHANOL, 98% MONOHYDRATE, 99% 12571 (+)-11ALPHA- 12557 (+)-DEHYDROISOANDROSTERONE, HYDROXYPROGESTERONE, 95% 97% 11630 (+)-2'-DEOXYURIDINE, 99+% 13433 (+)-DI-MU-CHLOROBIS(2-(1- 6153 (+)-2,3-O-BENZYLIDENE-D- (DIMETHYLAMINO)- THREITOL, 99% ETHYL)PHENYL-C,N)DIPALLADIU 10256 (+)-2,3-O-ISOPROPYLIDENE-2,3- 3845 (+)-DIACETYL-L-TARTARIC DIHYDROXY- 1,4- ANHYDRIDE, 97% BIS(DIPHENYLPHOSPHINO)BUT 12640 (+)-DIGITOXIGENIN, 98% 1260 (+)-2,3-O-ISOPROPYLIDENE-L- 12644 (+)-DIGOXIN, 97% THREITOL, 99% 2246 (+)-DIHYDROCARVONE, 98%, 12975 (+)-3',5'-O-(1,1,3,3- MIXTURE OF ISOMERS TETRAISOPROPYL-1,3- 12543 (+)-DIHYDROCHOLESTEROL, 96% DISILOXANEDIYL)CYTIDINE, 97% 8742 (+)-DIMETHYL 2,3-O- 8581 (+)-3,3',5-TRIIODO-L-THYRONINE, BENZYLIDENE-D- TARTRATE, 99% SODIUM SALT, 97% 3617 (+)-DIMETHYL 2,3-O- 2282 (+)-3- ISOPROPYLIDENE-D TARTRATE, (TRIFLUOROACETYL)CAMPHOR, 98% 98% 12675 (+)-EMETINE DIHYDROCHLORIDE HYDRATE, 97% 3757 (+)-GIBBERELLIC ACID, 90+% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 1 of 214 Aldrich Raman Condensed Phase Index Compound Name Index Compound Name 9003 (+)-GRISEOFULVIN 364 (+/-)-1,2-DIBROMO-3,3- 1192 (+)-LIMONENE OXIDE, 97%, DIMETHYLBUTANE, 97% MIXTURE OF CIS AND TRANS 402 (+/-)-1,2- 237 (+)-LONGIFOLENE, 98+% DIBROMOHEXAFLUOROPROPANE, 3932 (+)-MENTHYL CHLOROFORMATE 95% 4023 (+)-N,N'- 352 (+/-)-1,2-DIBROMOPROPANE, 97% DIALLYLTARTARDIAMIDE, 99+% 1028 (+/-)-1,2-DICHLOROETHYL ETHYL 9216 (+)-N,N'-DIBENZYL-L- ETHER, TECH., 90% TARTRAMIDE, 99% 1435 (+/-)-1,2-DIMETHYLPROPYLAMINE, 4040 (+)-N-ACETYLMURAMIC ACID, 98+% 97% 6003 (+/-)-1,2-DIPHENYL-2-PROPANOL, 10221 (+)- 98% NEOMENTHYLDIPHENYLPHOSPHI 639 (+/-)-1,2-DODECANEDIOL, 90% NE, TECH. 85% 5702 (+/-)-1,2-EPOXY-3- 1240 (+)-NOE-LACTOL DIMER, 99+% PHENOXYPROPANE, 99% 3097 (+)-OCTOPINE, 98% 627 (+/-)-1,2-HEXANEDIOL, 98% 6940 (+)-P-BROMOTETRAMISOLE 1176 (+/-)-1,3-BUTADIENE DIEPOXIDE, OXALATE, 99% 97% 792 (+)-P-MENTH-1-EN-9-OL, 97%, 606 (+/-)-1,3-BUTANEDIOL, 99% MIXTURE OF ISOMERS 2735 (+/-)-1,3- 4033 (+)-PANTOTHENIC ACID, CALCIUM CYCLOHEXANEDICARBOXYLIC SALT HYDRATE, 98% ACID, 98%, MIXTURE OF CIS AND 4032 (+)-PANTOTHENIC ACID, SODIUM TRANS SALT, 98% 1453 (+/-)-1,3-DIAMINOPENTANE, 98% 10660 (+)-PILOCARPINE 356 (+/-)-1,3-DIBROMOBUTANE, 98% HYDROCHLORIDE, 99% 847 (+/-)-1,4-DIBROMO-2,3- 6155 (+)-TRANS-A,A'-(2,2-DIMETHYL- BUTANEDIOL, 95% 1,3-DIOXOLANE-4,5- 6903 (+/-)-1-(1- DIYL)BIS(DIPHENYLMETHA NAPHTHYL)ETHYLAMINE, 98% 6995 (+)-TROGER'S BASE, 5753 (+/-)-1-(4-BROMOPHENOXY)-1- FLUKABRAND CHIRA- SELECT ETHOXYETHANE, TECH., 94% REAGENT, 99+% 6083 (+/-)-1-(4- 7663 (+)-USNIC ACID, 98% CHLOROPHENYL)ETHANOL, 98% 12553 (+)-VITAMIN D/3, CRYSTALLINE, 8716 (+/-)-1-ACETOXY-8-HYDROXY- 99+% 1,4,4A,9A- 5242 (+/-)-(1,2- TETRAHYDROANTHRAQUINONE, DIBROMOETHYL)BENZENE, 99% 98% 4940 (+/-)-(1- 4936 (+/-)-1-AMINOETHYLPHOSPHONIC AMINOBUTYL)PHOSPHONIC ACID, ACID, 96% 98% 8061 (+/-)-1- 5695 (+/-)-(2,3-EPOXYPROPYL)BENZENE, BENZOCYCLOBUTENECARBOXYL 98% IC ACID, 99% 808 (+/-)-(2-ENDO,3-EXO)- 359 (+/-)-1-BROMO-3-CHLORO-2- BICYCLO(2.2.2)OCT-5- ENE-2,3- METHYLPROPANE, 99% DIMETHANOL, 96% 722 (+/-)-1-CYCLOHEXYLETHANOL, 5954 (+/-)-1,1'-BI-2-NAPHTHOL, 99% 97% 10383 (+/-)-1,1'-BINAPHTHYL-2,2'-DIYL 4814 (+/-)-1-HYDROXY-2,5-DIOXO-3- HYDROGEN PHOSPHATE, 95% PYRROLIDINE- SULFONIC ACID, 3920 (+/-)-1,2,2,2-TETRACHLOROETHYL NA SALT HYDRA CHLORO- FORMATE, 98% 1175 (+/-)-1-METHOXY-2- 388 (+/-)-1,2,3,4- METHYLPROPYLENE OXIDE, 97% TETRACHLOROBUTANE, 97% 1060 (+/-)-1-METHOXY-2-PROPANOL, 8058 (+/-)-1,2,3,4-TETRAHYDRO-3- 98% ISOQUINOLINE- CARBOXYLIC 2722 (+/-)-1-METHYL-2-CYCLOHEXENE- ACID HYDROCHLORID 1-CARBOXYLIC ACID, 99% 860 (+/-)-1,2,3-TRIHYDROXYHEXANE, 6214 (+/-)-1-PHENYL-1,2-ETHANEDIOL, 99% 97% 608 (+/-)-1,2-BUTANEDIOL, 99% 6007 (+/-)-1-PHENYL-1-PROPANOL, 99% 6195 (+/-)-1-PHENYL-2-PENTANOL, 99% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 2 of 214 Aldrich Raman Condensed Phase Index Compound Name Index Compound Name 8697 (+/-)-1-PHENYLETHYL 851 (+/-)-2-CHLOROCYCLOHEXANOL, PROPIONATE, 98% TECH., 90% 4801 (+/-)-10-CAMPHORSULFONIC ACID, 3992 (+/-)-2-CHLOROPROPIONAMIDE, SODIUM SALT, 97% 98% 4842 (+/-)-10-CAMPHORSULFONYL 4543 (+/-)-2-CHLOROPROPIONITRILE, CHLORIDE, 98% 97% 6011 (+/-)-2,2-DIMETHYL-1-PHENYL-1- 2725 (+/-)-2-CIS,4-TRANS-ABSCISIC PROPANOL, 99% ACID, 98%, SYNTHETIC 846 (+/-)-2,3-DIBROMO-1,4- 1645 (+/-)-2- BUTANEDIOL, 99% DIMETHYLAMINOISOPROPYL 4546 (+/-)-2,3-DIBROMOPROPIONITRILE, CHLORIDE HYDROCHLORIDE, 98% TECH., 90% 1211 (+/-)-2- 6104 (+/-)-2,4-DICHLORO-ALPHA- ETHOXYTETRAHYDROFURAN, METHYLBENZYL ALCOHOL, 96% 99% 2168 (+/-)-2,4- 2477 (+/-)-2-ETHYLHEXANOIC ACID, DIMETHYLCYCLOPENTANONE, 99% 95%, MIXTURE OF CIS AND TRANS 3929 (+/-)-2-ETHYLHEXYL 3096 (+/-)-2,6-DIAMINOPIMELIC ACID, CHLOROFORMATE, 99% 98% 1442 (+/-)-2-ETHYLHEXYLAMINE, 98% 8067 (+/-)-2-(2- 558 (+/-)-2-HEPTANOL, 96% CHLOROPHENOXY)PROPIONIC 2616 (+/-)-2-HYDROXY-3- ACID, 98% METHYLBUTYRIC ACID, 99% 8082 (+/-)-2-(3- 2858 (+/-)-2-HYDROXYBUTYRIC ACID, CHLOROPHENOXY)PROPIONIC SODIUM SALT, 97% ACID, 98% 2620 (+/-)-2-HYDROXYCAPROIC ACID, 8128 (+/-)-2-(4- 99% CHLOROPHENOXY)PROPIONIC 2618 (+/-)-2-HYDROXYISOCAPROIC ACID, 98+% ACID, 99% 1931 (+/-)-2-(AMINOMETHYL)-15- 2863 (+/-)-2-HYDROXYVALERIC ACID, CROWN-5, 97% SODIUM SALT HYDRATE, 98% 1932 (+/-)-2-(AMINOMETHYL)-18- 6194 (+/-)-2-METHOXY-2- CROWN-6, 95% PHENYLETHANOL, 99% 1701 (+/-)-2-AMINO-1-BUTANOL, 97% 6046 (+/-)-2-METHOXY-ALPHA- 1653 (+/-)-2-AMINO-1- METHYLBENZYL ALCOHOL, 97% METHOXYPROPANE, 95% 1229 (+/-)-2- 1707 (+/-)-2-AMINO-3-METHYL-1- METHOXYTETRAHYDROPYRAN, BUTANOL, 97% 98% 1613 (+/-)-2-AMINONORBORNANE 2702 (+/-)-2-METHYL-1- HYDROCHLORIDE, 99% CYCLOHEXANECARBOXYLIC 7616 (+/-)-2-BENZYL-2- ACID, 99%, MIXTURE OF CIS AND (DIMETHYLAMINO)-4'- 7433 (+/-)-2-METHYL-1-INDANONE, 99% MORPHOLINOBUTYROPHENONE, 2468 (+/-)-2-METHYLBUTYRIC ACID, 97% 98% 1136 (+/-)-2-BROMO-1,1,3- 4508 (+/-)-2-METHYLGLUTARONITRILE, TRIMETHOXYPROPANE, 95% TECH., 80% 2583 (+/-)-2-BROMO-3-METHYLBUTYRIC 2473 (+/-)-2-METHYLVALERIC ACID, ACID, 97% 98% 2587 (+/-)-2-BROMOHEXANOIC ACID, 765 (+/-)-2-NORBORNANEMETHANOL, 97% 97%, MIXTURE OF ENDO AND EXO 2590 (+/-)-2-BROMOOCTANOIC ACID, 8028 (+/-)-2-PHENOXYPROPIONIC ACID, 97% 98+% 297 (+/-)-2-BROMOPENTANE, 95% 6014 (+/-)-2-PHENYL-1,2-PROPANEDIOL, 3993 (+/-)-2-BROMOPROPIONAMIDE, 97% 99% 6206 (+/-)-2-PHENYL-2-BUTANOL, 99% 3875 (+/-)-2-BROMOPROPIONYL 9613 (+/-)-2-PHENYLBUTYRONITRILE, CHLORIDE, TECH. 95% 547 (+/-)-2-BUTANOL, 99% 7431 (+/-)-2-PHENYLBUTYROPHENONE, 9089 (+/-)-2-CHLORO-2-PHENYLACETYL 98% CHLORIDE, TECH., 90% (c) 2007 Thermo Fisher Scientific Inc. All rights reserved. Page 3 of 214 Aldrich Raman Condensed Phase Index Compound Name Index Compound Name 7377 (+/-)-2- 2910 (+/-)-3-METHYL-2-OXOPENTANOIC PHENYLCYCLOHEPTANONE, 99% ACID, CALCIUM SALT 8555 (+/-)-2-PHENYLGLYCINE, 95% DIHYDRATE, 99% 5752 (+/-)-2- 2909 (+/-)-3-METHYL-2-OXOPENTANOIC PHENYLPROPIONALDEHYDE ACID, SODIUM SALT, 98+% DIMETHYL ACETAL, 99% 4208 (+/-)-3-METHYL-2- 1832 (+/-)-2-PIPERIDINEMETHANOL, 97% PYRROLIDINONE, 98% 4219 (+/-)-2-PYRROLIDONE-5- 2174 (+/-)-3-METHYLCYCLOHEXANONE, CARBOXYLIC ACID, 99% 97% 568 (+/-)-2-UNDECANOL, 97% 712 (+/-)-3-METHYLCYCLOPENTANOL, 1858 (+/-)-3,3,5- 99%, MIXTURE OF ISOMERS TRIMETHYLHEXAHYDROAZEPINE 2165 (+/-)-3- , 98%, MIXTURE OF ISOMERS METHYLCYCLOPENTANONE,
Load more

Recommended publications
  • Pest Management Strategic Plan for Strawberry Production in California
    PEST MANAGEMENT STRATEGIC PLAN FOR STRAWBERRY PRODUCTION IN CALIFORNIA 1 | Page TABLE OF CONTENTS INTRODUCTION ................................................................................................................................................... 5 Previous Pest Management Strategic Plan .............................................................................................. 5 Development of the New Plan .................................................................................................................... 5 STRAWBERRY MARKET SHARE AND VALUE.................................................................................................... 10 STRAWBERRY PRODUCTION OVERVIEW ........................................................................................................ 13 PEST MANAGEMENT FOR COMMERCIAL STRAWBERRY PLANTINGS ......................................................... 22 LAND PREPARATON THROUGH PLANTING ............................................................................................... 22 Activities Prior to Fumigation................................................................................................................. 22 Soil Fumigation ........................................................................................................................................ 22 Planting ..................................................................................................................................................... 25 Work Group Recommendations for
    [Show full text]
  • Pseudo-Cholinesterase in Rat Erythrocytes Basis of Its Substrate Ratio, It Is Possible That It May Be a Butyro-Cholinesterase
    No. 4535 September 29, 1956 NATURE 697 Pseudo-cholinesterase in Rat Erythrocytes basis of its substrate ratio, it is possible that it may be a butyro-cholinesterase. .ALTHOUGH there are many references in the literature to the existence of different types of cholin­ D.R. DAVIES esterase in mammalian sera1, it is generally believed J. P. RUTLAND 2 that human red cells contain only one type • Further­ more, we can find no evidence in the literature for Chemical Defence Experimental Establishment the existence of a pseudo-cholinesterase in any (Ministry of Supply), mammalian erythrocytes, although many workers Porton, Salisbury. have stated that benzoylcholine is hydrolysed by May 3. red cells. Since, however, the rate of hydrolysis is 1 Mundell, D. B., Nature, 153, 557 (1944). Ellis, S., Sanders, S., and slow, this breakdown of a substrate formerly presumed Bodansky, 0., J. Pharmacol., 91, 225 (1947). Levine M G and Suran, A. A., Enzymologia, 15, 17 (1951). ' · ., to be specific for pseudo-cholinesterase has been 'Mendell, B., Mundell, D. B., and Rudney, H., Biochem. J. 37 473 attributed to true cholinesterase. Indeed, Adams3 (1943). ' ' has shown that purified true cholinesterase does • Adams, D. H., Bwchim. Biophys. Acta, ~. 1 (1949). hydrolyse benzoylcholine, at a rate which would • Fraser, P. ~-, ti:,esis, University of Birmingham (1951), and private commumcat10n (1956). account for such observations. In spite of this, • Aldridge, W. N., Biochem. J., 53, 62 (1953). Austin, L., and Berry some results obtained by Fraser with benzoylcholine• W. K., Bwchem. J., 54, 695 (1953). ' imply the existence of more than one type of cholin­ 'Bayliss, B.
    [Show full text]
  • Aldrich FT-IR Collection Edition I Library
    Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL
    [Show full text]
  • The Anxiomimetic Properties of Pentylenetetrazol in the Rat
    University of Rhode Island DigitalCommons@URI Open Access Dissertations 1980 THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT Gary Terence Shearman University of Rhode Island Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Shearman, Gary Terence, "THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT" (1980). Open Access Dissertations. Paper 165. https://digitalcommons.uri.edu/oa_diss/165 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. THE ANXIOMIMETIC PROPERTIES OF PENTYLENETETRAZOL IN THE RAT BY GARY TERENCE SHEARMAN A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN PHARMACEUTICAL SCIENCES (PHARMACOLOGY AND TOXICOLOGY) UNIVERSITY OF RHODE ISLAND 19 80 DOCTOR OF PHILOSOPHY DISSERT.A.TION OF GARY TERENCE SHEAffiil.AN Approved: Dissertation Cormnittee \\ Major Professor ~~-L_-_._dd__· _... _______ _ -~ar- Dean of the Graduate School UNIVERSITY OF RHODE ISLAND 1980 ABSTRACT Investigation of the biological basis of anxiety is ham­ pered by the lack of an appropriate animal model for research purposes. There are no known drugs that cause anxiety in laboratory animals. Pentylenetetrazol (PTZ) produces intense anxiety in human volunteers (Rodin, 1958; Rodin and Calhoun, 1970). Therefore, it was the major objective of this disser- tation to test the hypothesis that the discriminative stimu­ lus produced by PTZ in the rat was related to its anxiogenic action in man. It was also an objective to suggest the neuro- chemical basis for the discriminative stimulus property of PTZ through appropriate drug interactions.
    [Show full text]
  • Inhaled Nitric Oxide Therapy in Adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans
    Available online http://ccforum.com/content/13/3/212 Review Bench-to-bedside review: Inhaled nitric oxide therapy in adults Benedict C Creagh-Brown, Mark JD Griffiths and Timothy W Evans Unit of Critical Care, Faculty of Medicine, Imperial College, London, UK and Adult Intensive Care Unit, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK Corresponding author: Timothy W Evans, [email protected] Published: 29 May 2009 Critical Care 2009, 13:212 (doi:10.1186/cc7734) This article is online at http://ccforum.com/content/13/3/221 © 2009 BioMed Central Ltd Abstract Administration of inhaled nitric oxide to adults Nitric oxide (NO) is an endogenous mediator of vascular tone and The licensed indication of iNO is restricted to persistent host defence. Inhaled nitric oxide (iNO) results in preferential pulmonary hypertension in neonates, yet most iNO is pulmonary vasodilatation and lowers pulmonary vascular resis- administered for unlicensed indications. Pharmaceutical iNO tance. The route of administration delivers NO selectively to is available at a very high cost, and in light of this and ventilated lung units so that its effect augments that of hypoxic concerns over potential adverse effects of iNO, international pulmonary vasoconstriction and improves oxygenation. This guidelines have been developed. An advisory board under the ‘Bench-to-bedside’ review focuses on the mechanisms of action of iNO and its clinical applications, with emphasis on acute lung injury auspices of the European Society of Intensive Care Medicine and the acute respiratory distress syndrome. Developments in our and the European Association of Cardiothoracic Anaes- understanding of the cellular and molecular actions of NO may thesiologists published its recommendations in 2005 [1].
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • A Study on Physical Chemistry of Solid a Mmonium Materials for Nox Reduction of Diesel Engine Emissions
    A Study on Physical Chemistry of Solid A mmonium Materials for NOx Reduction of Diesel Engine Emissions Cheon Seog (Steve) Yoon and Jong Kook Shin Hannam University, Daejeon, KOREA Hoyeol Lee and Hongsuk Kim Korea Institute of Machinery & Materials, Daejeon, KOREA 2014 DOE CLEERS Workshop University of Michigan, Dearborn, MI, USA 1 Table of Contents • Introduction of Solid SCR System • Ammonium Salts • Chemical Reactions, Decomposition Chemistry • Chemical Kinetic Parameters by TGA, DTA and DSC • Decomposition Rate from Hot Plate Test and Chemical Kinetic Parameters • Simple Reactor with Visible Window • Equilibrium Vapor Pressure Curve for Ammonium Carbonate • Acquisition of Re-solidified Materials from Ammonium Carbonate • Analytical Study of Re-solidified Materials from Ammonium Carbonate by XRD, FT-IR, and EA • Concluding Remarks • Acknowledgement • Reference 2 Solid SCR System • NOx purification technology by using NH3, which is generated from solid ammonium. • Ammonium carbonate, (NH4)2CO3 , is solid at room temperature, and it decomposes into NH3, H2O & CO2 above temperature of 60℃. 3 Material Properties of Ammonium Salts Solid urea Ammonium carbonate Ammonium cabarmate Molecular formula (NH2)2CO (NH4)2CO3 NH2COONH4 Molecular weight 60.07 96.09 78.07 3 Density, g/cm 1.33 1.5 1.6 Mols NH3 per Mol 2 2 2 Mols NH3 per kg 33.3 20.8 25.6 Decomposition temp., ℃ 140 58 60 NH2CONH2↔ NH3+HNCO Reaction mechanism (NH4)2CO3↔2NH3+CO2+H2O NH4COONH2 ↔ 2NH3 + CO2 HNCO +H2O ↔ NH3 + CO2 Cost cheap cheap moderate * HNCO: Isocyanic Acid [ref] G. Fulks,
    [Show full text]
  • Aldrich Raman
    Aldrich Raman Library Listing – 14,033 spectra This library represents the most comprehensive collection of FT-Raman spectral references available. It contains many common chemicals found in the Aldrich Handbook of Fine Chemicals. To create the Aldrich Raman Condensed Phase Library, 14,033 compounds found in the Aldrich Collection of FT-IR Spectra Edition II Library were excited with an Nd:YVO4 laser (1064 nm) using laser powers between 400 - 600 mW, measured at the sample. A Thermo FT-Raman spectrometer (with a Ge detector) was used to collect the Raman spectra. The spectra were saved in Raman Shift format. Aldrich Raman Index Compound Name Index Compound Name 4803 ((1R)-(ENDO,ANTI))-(+)-3- 4246 (+)-3-ISOPROPYL-7A- BROMOCAMPHOR-8- SULFONIC METHYLTETRAHYDRO- ACID, AMMONIUM SALT PYRROLO(2,1-B)OXAZOL-5(6H)- 2207 ((1R)-ENDO)-(+)-3- ONE, BROMOCAMPHOR, 98% 12568 (+)-4-CHOLESTEN-3-ONE, 98% 4804 ((1S)-(ENDO,ANTI))-(-)-3- 3774 (+)-5,6-O-CYCLOHEXYLIDENE-L- BROMOCAMPHOR-8- SULFONIC ASCORBIC ACID, 98% ACID, AMMONIUM SALT 11632 (+)-5-BROMO-2'-DEOXYURIDINE, 2208 ((1S)-ENDO)-(-)-3- 97% BROMOCAMPHOR, 98% 11634 (+)-5-FLUORODEOXYURIDINE, 769 ((1S)-ENDO)-(-)-BORNEOL, 99% 98+% 13454 ((2S,3S)-(+)- 11633 (+)-5-IODO-2'-DEOXYURIDINE, 98% BIS(DIPHENYLPHOSPHINO)- 4228 (+)-6-AMINOPENICILLANIC ACID, BUTANE)(N3-ALLYL)PD(II) CL04, 96% 97 8167 (+)-6-METHOXY-ALPHA-METHYL- 10297 ((3- 2- NAPHTHALENEACETIC ACID, DIMETHYLAMINO)PROPYL)TRIPH 98% ENYL- PHOSPHONIUM BROMIDE, 12586 (+)-ANDROSTA-1,4-DIENE-3,17- 99% DIONE, 98% 13458 ((R)-(+)-2,2'- 963 (+)-ARABINOGALACTAN BIS(DIPHENYLPHOSPHINO)-1,1'-
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC
    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
    [Show full text]
  • Environmental Protection Agency § 117.3
    Environmental Protection Agency § 117.3 (4) Applicability date. This paragraph TABLE 117.3—REPORTABLE QUANTITIES OF (i) is applicable beginning on February HAZARDOUS SUBSTANCES DESIGNATED PUR- 6, 2020. SUANT TO SECTION 311 OF THE CLEAN (j) Process waste water means any WATER ACT—Continued water which, during manufacturing or Cat- RQ in pounds processing, comes into direct contact Material egory (kilograms) with or results from the production or use of any raw material, intermediate Ammonium benzoate ...................... D ...... 5,000 (2,270) Ammonium bicarbonate .................. D ...... 5,000 (2,270) product, finished product, byproduct, Ammonium bichromate ................... A ....... 10 (4.54) or waste product. Ammonium bifluoride ...................... B ....... 100 (45.4) Ammonium bisulfite ......................... D ...... 5,000 (2,270) [44 FR 50776, Aug. 29, 1979, as amended at 58 Ammonium carbamate .................... D ...... 5,000 (2,270) FR 45039, Aug. 25, 1993; 65 FR 30904, May 15, Ammonium carbonate ..................... D ...... 5,000 (2,270) 2000; 80 FR 37112, June 29, 2015; 83 FR 5208, Ammonium chloride ........................ D ...... 5,000 (2,270) Feb. 6, 2018] Ammonium chromate ...................... A ....... 10 (4.54) Ammonium citrate dibasic ............... D ...... 5,000 (2,270) Ammonium fluoborate ..................... D ...... 5,000 (2,270) § 117.2 Abbreviations. Ammonium fluoride ......................... B ....... 100 (45.4) NPDES equals National Pollutant Ammonium hydroxide ..................... C
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]